Related Experiment Video
Updated: May 12, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Treatment of hepatitis C virus infection in the future
Tatsuo Kanda1, Osamu Yokosuka, Masao Omata
1Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba (260-8670), Japan. kanda2t@yahoo.co.jp.
Abstract:
Two direct-acting antivirals (DAAs) against hepatitis C virus (HCV): telaprevir and boceprevir, are now available in combination with peginterferon plus ribavirin for the treatment of chronic hepatitis C infection. Although these drugs are potent inhibitors of HCV replication, they occasionally result in severe adverse events. In the present clinical trials, in their stead, several second-generation DAAs are being investigated. Most of them are being viewed with high expectations, but they also require the combination with peginterferon plus ribavirin. In the near future, we might be using all-oral DAAs and interferon-free regimens for the treatment of HCV-infected patients, and these would be potent inhibitors of HCV and have less adverse events.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Microorganisms in Medicine and Therapeutics
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

